-
公开(公告)号：US06441156B1
公开(公告)日：2002-08-27
申请号：US09470443
申请日：1999-12-22
Applicant: Michael Isaac Lerman , Farida Latif , Ming-Hui Wei , Fuh-Mei Duh , John Dorrance Minna , Yoshitaka Sekido , Boning Gao
Inventor： Michael Isaac Lerman , Farida Latif , Ming-Hui Wei , Fuh-Mei Duh , John Dorrance Minna , Yoshitaka Sekido , Boning Gao
IPC: C07H2102
CPC classification number: C07K14/705 , A61K38/00
Abstract: The present invention relates to calcium channel compositions and methods of making and using same. In particular, the invention relates to calcium channel alpha2delta (&agr;2&dgr;) subunits and nucleic acid sequences encoding them. These compositions are useful in methods for identifying compounds that modulate the activity of calcium channels and for identifying compounds as therapeutic for disease.
Abstract translation: 本发明涉及钙通道组合物及其制备和使用方法。 特别地，本发明涉及钙通道α2δ（α2delta）亚基和编码它们的核酸序列。 这些组合物可用于鉴定调节钙通道活性并鉴定化合物作为疾病治疗的化合物的方法。
-
2.发明授权公开(公告)号：US07951356B1
公开(公告)日：2011-05-31
申请号：US09573835
申请日：2000-05-18
Applicant: Philip E. Thorpe , Steven W. King , Boning Gao
Inventor： Philip E. Thorpe , Steven W. King , Boning Gao
CPC classification number: A61K47/6813 , A61K47/6435 , Y10S514/834 , Y10S530/827 , Y10S530/829
Abstract: The invention embodies the surprising discovery that Tissue Factor (TF) compositions and variants thereof specifically localize to the blood vessels within a vascularized tumor following systemic administration. The invention therefore provides methods and compositions comprising coagulant-deficient Tissue Factor for use in effecting specific coagulation and for use in tumor treatment. The TF compositions and methods of present invention may be used alone, as TF conjugates with improved half-life, or in combination with other agents, such as conventional chemotherapeutic drugs, targeted immunotoxins, targeted coaguligands, and/or in combination with Factor VIIa (FVIIa) or FVIIa activators.
Abstract translation: 本发明体现了惊人的发现：组织因子（TF）组合物及其变体在全身给药后特异性定位于血管化肿瘤内的血管。 因此，本发明提供了用于实现特异性凝结和用于肿瘤治疗的用于组合凝血剂的组织因子的方法和组合物。 本发明的TF组合物和方法可以单独使用，作为具有改善的半衰期的TF缀合物，或与其它试剂（例如常规化学治疗药物，靶向免疫毒素，靶向凝固配体）和/或与因子VIIa组合 FVIIa）或FVIIa激活剂。
-
Patent Agency Ranking3.发明授权Combined tissue factor and chemotherapeutic methods and compositions for coagulation and tumor treatment 失效组合因子和化学治疗方法和组合物用于凝血和肿瘤治疗
公开(公告)号：US6132729A
公开(公告)日：2000-10-17
申请号：US9217
申请日：1998-01-20
Applicant: Philip E. Thorpe , Steven W. King , Boning Gao
Inventor： Philip E. Thorpe , Steven W. King , Boning Gao
IPC: A61K45/00 , A61K38/00 , A61K47/48 , A61P7/02 , A61P35/00 , A61K39/00 , A61K39/395 , C07K14/00 , C07K35/14
CPC classification number: A61K47/48423 , A61K47/48292 , Y10S514/834 , Y10S530/827 , Y10S530/829
Abstract: The invention embodies the surprising discovery that Tissue Factor (TF) compositions and variants thereof specifically localize to the blood vessels within a vascularized tumor following systemic administration. The invention therefore provides methods and compositions comprising coagulation-deficient Tissue Factor for use in effecting specific coagulation and for use in tumor treatment. The TF compositions and methods of present invention may be used alone, as TF conjugates with improved half-life, or in combination with other agents, such as conventional chemotherapeutic drugs, targeted immunotoxins, targeted coaguligands, and/or in combination with Factor VIIa (FVIIa) or FVII activators.
Abstract translation: 本发明体现了惊人的发现：组织因子（TF）组合物及其变体在全身给药后特异性定位于血管化肿瘤内的血管。 因此，本发明提供了用于实现特异性凝结和用于肿瘤治疗的凝血缺陷组织因子的方法和组合物。 本发明的TF组合物和方法可以单独使用，作为具有改善的半衰期的TF缀合物，或与其它试剂（例如常规化学治疗药物，靶向免疫毒素，靶向凝固配体）和/或与因子VIIa组合 FVIIa）或FVII激活剂。
-
公开(公告)号：US06979724B2
公开(公告)日：2005-12-27
申请号：US10116949
申请日：2002-04-05
Applicant: Michael Isaac Lerman , Farida Latif , Ming-Hui Wei , Fuh-Mei Duh , John Dorrance Minna , Yoshitaka Sekido , Boning Gao
Inventor： Michael Isaac Lerman , Farida Latif , Ming-Hui Wei , Fuh-Mei Duh , John Dorrance Minna , Yoshitaka Sekido , Boning Gao
IPC: A61K38/00 , C07K14/705 , C07K14/435 , A61K38/17 , C07H21/04
CPC classification number: C07K14/705 , A61K38/00
Abstract: The present invention relates to calcium channel compositions and methods of making and using same. In particular, the invention relates to calcium channel alpha2delta (α2δ) subunits and nucleic acid sequences encoding them. These compositions are useful in methods for identifying compounds that modulate the activity of calcium channels and for identifying compounds as therapeutic for disease.
Abstract translation: 本发明涉及钙通道组合物及其制备和使用方法。 特别地，本发明涉及钙通道α2δ（α2Δ3）亚基和编码它们的核酸序列。 这些组合物可用于鉴定调节钙通道活性并鉴定化合物作为疾病治疗的化合物的方法。
-
5.发明授权
公开(公告)号：US6156321A
公开(公告)日：2000-12-05
申请号：US9822
申请日：1998-01-20
Applicant: Philip E. Thorpe , Steven W. King , Boning Gao
Inventor： Philip E. Thorpe , Steven W. King , Boning Gao
IPC: A61K45/00 , A61K38/00 , A61K47/48 , A61P7/02 , A61P35/00 , A61K39/395 , A61K35/16 , A61K39/00 , C07K14/00
CPC classification number: A61K47/48423 , A61K47/48292 , Y10S514/834 , Y10S530/827 , Y10S530/829
Abstract: The invention embodies the surprising discovery that Tissue Factor (TF) compositions and variants thereof specifically localize to the blood vessels within a vascularized tumor following systemic administration. The invention therefore provides methods and compositions comprising coagulant-deficient Tissue Factor for use in effecting specific coagulation and for use in tumor treatment. The TF compositions and methods of present invention may be used alone, as TF conjugates with improved half-life, or in combination with other agents, such as conventional chemotherapeutic drugs, targeted immunotoxins, targeted coaguligands, and/or in combination with Factor VIIa (FVIIa) or FVIIa activators.
Abstract translation: 本发明体现了惊人的发现：组织因子（TF）组合物及其变体在全身给药后特异性定位于血管化肿瘤内的血管。 因此，本发明提供了用于实现特异性凝结和用于肿瘤治疗的用于组合凝血剂的组织因子的方法和组合物。 本发明的TF组合物和方法可以单独使用，作为具有改善的半衰期的TF缀合物，或与其它试剂（例如常规化学治疗药物，靶向免疫毒素，靶向凝固配体）和/或与因子VIIa组合 FVIIa）或FVIIa激活剂。
-
6.发明授权Combined tissue factor and factor VIIa methods and compositions for coagulation and tumor treatment 失效组合因子和凝血因子Ⅶa组合物用于凝血和肿瘤治疗
公开(公告)号：US6132730A
公开(公告)日：2000-10-17
申请号：US9656
申请日：1998-01-20
Applicant: Philip E. Thorpe , Steven W. King , Boning Gao
Inventor： Philip E. Thorpe , Steven W. King , Boning Gao
IPC: A61K45/00 , A61K38/00 , A61K47/48 , A61P7/02 , A61P35/00 , A61K39/00 , A61K35/14 , A61K39/395 , C07K14/00
CPC classification number: A61K47/48423 , A61K47/48292 , Y10S514/834 , Y10S530/827 , Y10S530/829
Abstract: The invention embodies the surprising discovery that Tissue Factor (TF) compositions and variants thereof specifically localize to the blood vessels within a vascularized tumor following systemic administration. The invention therefore provides methods and compositions comprising coagulation-deficient Tissue Factor for use in effecting specific coagulation and for use in tumor treatment. The TF compositions and methods of present invention may be used alone, as TF conjugates with improved half-life, or in combination with other agents, such as conventional chemotherapeutic drugs, targeted immunotoxins, targeted coaguligands, and/or in combination with Factor VIIa (FVIIa) or FVII activators.
Abstract translation: 本发明体现了惊人的发现：组织因子（TF）组合物及其变体在全身给药后特异性定位于血管化肿瘤内的血管。 因此，本发明提供了用于实现特异性凝结和用于肿瘤治疗的凝血缺陷组织因子的方法和组合物。 本发明的TF组合物和方法可以单独使用，作为具有改善的半衰期的TF缀合物，或与其它试剂（例如常规化学治疗药物，靶向免疫毒素，靶向凝固配体）和/或与因子VIIa组合 FVIIa）或FVII激活剂。
-
公开(公告)号：US07101557B2
公开(公告)日：2006-09-05
申请号：US10375741
申请日：2003-02-27
Applicant: Philip E. Thorpe , Steven W. King , Boning Gao
Inventor： Philip E. Thorpe , Steven W. King , Boning Gao
IPC: A61K39/00 , A61K39/40 , A61K39/395 , A01N25/00 , C07K1/00
CPC classification number: A61K47/6813 , A61K47/6435 , Y10S514/834 , Y10S530/827 , Y10S530/829
Abstract: The invention embodies the surprising discovery that Tissue Factor (TF) compositions and variants thereof specifically localize to the blood vessels within a vascularized tumor following systemic administration. The invention therefore provides methods and compositions comprising coagulant-deficient Tissue Factor for use in effecting specific coagulation and for use in tumor treatment. The TF compositions and methods of present invention may be used alone, as TF conjugates with improved half-life, or in combination with other agents, such as conventional chemotherapeutic drugs, targeted immunotoxins, targeted coaguligands, and/or in combination with Factor VIIa (FVIIa) or FVIIa activators.
-
-
-
-
-
-
Search Results
7
records
(took 0.028 seconds)
